FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency
Silver Spring, Maryland—(ENEWSPF)—July 19, 2018
Contact: Sandy Walsh
The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer,…
